This protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient’s contract at the time the services are rendered.

### DESCRIPTION

Intestinal dysbiosis may be defined as a state of disordered microbial ecology that is believed to cause disease. Laboratory analysis of fecal samples is proposed as a method of identifying individuals with intestinal dysbiosis and other gastrointestinal disorders.

### SUMMARY OF EVIDENCE

For individuals who have gastrointestinal conditions such as suspected intestinal dysbiosis, irritable bowel syndrome, malabsorption, or small intestinal bacterial overgrowth who receive fecal analysis testing, the evidence includes several cohort and case-control studies comparing fecal microbiota in patients who had a known disease with healthy controls. The relevant outcomes are test validity, symptoms, and functional outcomes. The available retrospective cohort studies on fecal analysis have suggested that some components of the fecal microbiome and inflammatory markers may differ across patients with irritable bowel syndrome subtypes. No studies were identified on the diagnostic accuracy of fecal analysis vs. another diagnostic approach or that compared health outcomes in patients managed with and without fecal analysis tests. No studies were identified that directly informed the use of fecal analysis in the evaluation of intestinal dysbiosis, malabsorption, or small intestinal bacterial overgrowth. The evidence is insufficient to determine the effects of the technology on health outcomes.

### POLICY

Fecal analysis of the following components is considered investigational as a diagnostic test for the evaluation of intestinal dysbiosis, irritable bowel syndrome, malabsorption, or small intestinal overgrowth of bacteria:
• Triglycerides
• Chymotrypsin
• Iso-butyrate, iso-valerate, and n-valerate
• Meat and vegetable fibers
• Long-chain fatty acids
• Cholesterol
• Total short-chain fatty acids
• Levels of Lactobacilli, bifidobacteria, and Escherichia coli and other “potential pathogens,” including Aeromonas, Bacillus cereus, Campylobacter, Citrobacter, Klebsiella, Proteus, Pseudomonas, Salmonella, Shigella, Staphylococcus aureus, and Vibrio
• Identification and quantitation of fecal yeast (including Candida albicans, Candida tropicalis, Rhodotorula, and Geotrichum)
• N-butyrate
• β-glucuronidase
• pH
• Short-chain fatty acid distribution (adequate amount and proportions of the different short-chain fatty acids reflect the basic status of intestinal metabolism)
• Fecal secretory immunoglobulin A.

BACKGROUND

INTESTINAL DYSBIOSIS

The gastrointestinal tract is colonized by a large number and variety of microorganisms including bacteria, fungi, and archaea. The concept of intestinal dysbiosis rests on the assumption that abnormal patterns of intestinal flora, such as overgrowth of some commonly found microorganisms, have an impact on human health. Symptoms and conditions attributed to intestinal dysbiosis include chronic disorders (e.g., irritable bowel syndrome, inflammatory or autoimmune disorders, food allergy, atopic eczema, unexplained fatigue, arthritis, ankylosing spondylitis), malnutrition, or neuropsychiatric symptoms (e.g., autism), and breast and colon cancer.

The gastrointestinal tract symptoms attributed to intestinal dysbiosis (i.e., bloating, flatulence, diarrhea, constipation) overlap in part with either irritable bowel syndrome or small intestinal bacterial overgrowth syndrome. The diagnosis of irritable bowel syndrome is typically made clinically, based on a set of criteria referred to as the Rome criteria. The small intestine normally contains a limited number of bacteria, at least as compared with the large intestine. Small intestine bacterial overgrowth may occur due to altered motility (including blind loops), decreased acidity, exposure to antibiotics, or surgical resection of the small bowel. Symptoms include malabsorption, diarrhea, fatigue, and lethargy. The laboratory criterion standard for diagnosis consists of the culture of a jejunal fluid sample, but this requires invasive testing. Hydrogen breath tests, commonly used to evaluate lactose intolerance, have been adapted for use in diagnosing small intestinal bacterial overgrowth.

Fecal Markers of Dysbiosis

Laboratory analysis of both stool and urine has been investigated as markers of dysbiosis. Reference laboratories specializing in the evaluation of dysbiosis may offer comprehensive testing of various aspects of digestion,
absorption, microbiology, and metabolic markers. For example, Genova Diagnostics\(^1\) offers the Comprehensive Digestive Stool Analysis 2.0 test, which evaluates a stool sample for components listed in Table 1.

Table 1. Components of the Comprehensive Digestive Stool Analysis 2.0 Test

<table>
<thead>
<tr>
<th>Markers</th>
<th>Analytes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Digestion</td>
<td>• Triglycerides</td>
</tr>
<tr>
<td></td>
<td>• Chymotrypsin</td>
</tr>
<tr>
<td></td>
<td>• Iso-butyrate, iso-valerate, and n-valerate</td>
</tr>
<tr>
<td></td>
<td>• Meat and vegetable fibers</td>
</tr>
<tr>
<td>Absorption</td>
<td>Long-chain fatty acids</td>
</tr>
<tr>
<td></td>
<td>Cholesterol</td>
</tr>
<tr>
<td></td>
<td>Total fecal fat</td>
</tr>
<tr>
<td></td>
<td>Total short-chain fatty acids</td>
</tr>
<tr>
<td>Microbiology</td>
<td>• Levels of Lactobacilli, bifidobacteria, and Escherichia coli and other “potential pathogens,” including Aeromonas, Bacillus cereus, Campylobacter, Citrobacter, Klebsiella, Proteus, Pseudomonas, Salmonella, Shigella, Staphylococcus aureus, and Vibrio</td>
</tr>
<tr>
<td></td>
<td>• Identification and quantitation of fecal yeast (including Candida albicans, Candida tropicalis, Rhodotorula, and Geotrichum)</td>
</tr>
<tr>
<td>Metabolic</td>
<td>N-butyrate (considered key energy source for colonic epithelial cells)</td>
</tr>
<tr>
<td></td>
<td>β-glucuronidase</td>
</tr>
<tr>
<td></td>
<td>• pH</td>
</tr>
<tr>
<td></td>
<td>• Short-chain fatty acid distribution (adequate amount and proportions of the different short-chain fatty acids reflect the basic status of intestinal metabolism)</td>
</tr>
<tr>
<td>Immunology</td>
<td>• Fecal secretory immunoglobulin A (as a measure of luminal immunologic function)</td>
</tr>
<tr>
<td></td>
<td>• Calprotectin</td>
</tr>
</tbody>
</table>

The comprehensive stool analysis package has an optional parasitology component.

A related topic, fecal microbiota transplantation, the infusion of intestinal microorganisms to restore normal intestinal flora, is addressed in the Fecal Microbiota Transplantation Protocol. Fecal microbiota transplantation has been rigorously studied for the treatment of patients with recurrent Clostridium difficile infection. No specific stool testing, other than the identification of Clostridium difficile infection, is currently recommended.

**REGULATORY STATUS**

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of comprehensive testing for fecal dysbiosis.

**RELATED PROTOCOL**

Fecal Microbiota Transplantation

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. *For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.*
It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.

REFERENCES

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.